JP Morgan Chase
FULC icon

JP Morgan Chase’s Fulcrum Therapeutics FULC Stock Holding History

JP Morgan Chase’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,800
Closed -$22.6K – 7443
2024
Q4 		$22.6K Hold
4,800
– – ﹤0.01% 6229
2024
Q3 		$17.1K Sell
4,800
-4,000
-45% -$29.7K ﹤0.01% 6266
2024
Q2 		$54.6K Buy
+8,800
New +$66.7K ﹤0.01% 5818

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

JP Morgan Chase's FULC Position: Q1 2026 in Review

JP Morgan Chase increased its Fulcrum Therapeutics (FULC) stake by 43% in Q1 2026, buying an estimated $83.5K and bringing the position to 29,792 shares worth $196K. The position accounts for ﹤0.01% of the portfolio, ranked #5480.

JP Morgan Chase first reported a position in FULC in Q3 2019 and has held it in 27 quarters since. The position peaked at $4.9M in Q3 2021. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • JP Morgan Chase held 29,792 shares of Fulcrum Therapeutics worth $196K as of Q1 2026.
  • JP Morgan Chase bought 9,003 Fulcrum Therapeutics shares in Q1 2026, an estimated $83.5K.
  • Fulcrum Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #5480 holding.
  • JP Morgan Chase first reported a position in Fulcrum Therapeutics in Q3 2019 and has held it in 27 quarters since.
  • JP Morgan Chase's Fulcrum Therapeutics position peaked at $4.9M in Q3 2021.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.